Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial

Wagner S. Brum; Kieran F. Docherty; Nicholas J. Ashton; Henrik Zetterberg; Oskar Hansson; John J.V. McMurray; Kaj Blennow

doi:10.1001/jamaneurol.2023.4719

Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial

Wagner S. Brum, Kieran F. Docherty, Nicholas J. Ashton, Henrik Zetterberg, Oskar Hansson, John J.V. McMurray, Kaj Blennow

Research output: Contribution to journal › Article › peer-review

Abstract

Amyloid-β (Aβ) accumulation is critical in Alzheimer disease (AD), and neprilysin is involved in physiologically clearing Aβ. Concerns exist regarding long-term use of sacubitril/valsartan, a neprilysin inhibitor and angiotensin receptor blocker used for heart failure, and its potential to increase AD risk. We evaluated neprilysin inhibition’s effect on AD blood biomarkers in patients with coronary heart disease.

Original language	English
Article number	197
Journal	JAMA Neurology
Volume	81
Issue number	2
Early online date	2024
DOIs	https://doi.org/10.1001/jamaneurol.2023.4719
Publication status	Published - 2024

Subject classification (UKÄ)

Neurosciences

Access to Document

10.1001/jamaneurol.2023.4719

Cite this

@article{e07ae7ef337e4453afce256d6cfd3dfb,

title = "Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial",

abstract = "Amyloid-β (Aβ) accumulation is critical in Alzheimer disease (AD), and neprilysin is involved in physiologically clearing Aβ. Concerns exist regarding long-term use of sacubitril/valsartan, a neprilysin inhibitor and angiotensin receptor blocker used for heart failure, and its potential to increase AD risk. We evaluated neprilysin inhibition{\textquoteright}s effect on AD blood biomarkers in patients with coronary heart disease.",

author = "Brum, {Wagner S.} and Docherty, {Kieran F.} and Ashton, {Nicholas J.} and Henrik Zetterberg and Oskar Hansson and McMurray, {John J.V.} and Kaj Blennow",

year = "2024",

doi = "10.1001/jamaneurol.2023.4719",

language = "English",

volume = "81",

journal = "JAMA Neurology",

issn = "2168-6149",

publisher = "American Medical Association",

number = "2",

}

TY - JOUR

T1 - Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers

T2 - A Secondary Analysis of a Randomized Clinical Trial

AU - Brum, Wagner S.

AU - Docherty, Kieran F.

AU - Ashton, Nicholas J.

AU - Zetterberg, Henrik

AU - Hansson, Oskar

AU - McMurray, John J.V.

AU - Blennow, Kaj

PY - 2024

Y1 - 2024

N2 - Amyloid-β (Aβ) accumulation is critical in Alzheimer disease (AD), and neprilysin is involved in physiologically clearing Aβ. Concerns exist regarding long-term use of sacubitril/valsartan, a neprilysin inhibitor and angiotensin receptor blocker used for heart failure, and its potential to increase AD risk. We evaluated neprilysin inhibition’s effect on AD blood biomarkers in patients with coronary heart disease.

AB - Amyloid-β (Aβ) accumulation is critical in Alzheimer disease (AD), and neprilysin is involved in physiologically clearing Aβ. Concerns exist regarding long-term use of sacubitril/valsartan, a neprilysin inhibitor and angiotensin receptor blocker used for heart failure, and its potential to increase AD risk. We evaluated neprilysin inhibition’s effect on AD blood biomarkers in patients with coronary heart disease.

U2 - 10.1001/jamaneurol.2023.4719

DO - 10.1001/jamaneurol.2023.4719

M3 - Article

C2 - 38109077

AN - SCOPUS:85181027456

SN - 2168-6149

VL - 81

JO - JAMA Neurology

JF - JAMA Neurology

IS - 2

M1 - 197

ER -

Effect of Neprilysin Inhibition on Alzheimer Disease Plasma Biomarkers: A Secondary Analysis of a Randomized Clinical Trial

Abstract

Subject classification (UKÄ)

Access to Document

Fingerprint

Cite this